Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

BACKGROUND: Multiple myeloma, a malignancy of the antibody-secreting plasma cells, remains incurable by current therapy. However, the proteasome inhibitor bortezomib and other new drugs are revolutionizing its treatment. It remains unclear why myelomas are peculiarly sensitive to bortezomib, or what...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ling, Silvia C. W., Lau, Edwin K. K., Al-Shabeeb, Ammira, Nikolic, Angela, Catalano, Albert, Iland, Harry, Horvath, Noemi, Ho, P. Joy, Harrison, Simon, Fleming, Shaun, Joshua, Douglas E., Allen, John D.
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2012
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3248932/
https://ncbi.nlm.nih.gov/pubmed/21993678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.043331
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados